Conscience April 2025 Policy Brief - FDA Announces Plan to Phase Out Animal Testing Requirement for Drug Development

FDA Announces Plan to Phase Out Animal Testing Requirement for Drug Development On April 10, the US Food and Drug Administration (FDA) announced that it would begin the process of phasing out animal testing in the development of monoclonal antibody therapies and other drugs to reduce research and development costs and, by extension, drug prices This policy brief describes how the new regulations relate to current and pending legislation, the alternative sources data can be derived from, and how this new regime could lead to cost savings in drug development.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-04-28
DOI
https://doi.org/10.5281/zenodo.15298834
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Conscience April 2025 Policy Brief - FDA Announces Plan to Phase Out Animal Testing Requirement for Drug Development

Zenodo (CERN European Organization for Nuclear Research)
Monoclonal and Polyclonal Antibodies Research
article

Conscience April 2025 Policy Brief - FDA Announces Plan to Phase Out Animal Testing Requirement for Drug Development

article en

Abstract

FDA Announces Plan to Phase Out Animal Testing Requirement for Drug Development On April 10, the US Food and Drug Administration (FDA) announced that it would begin the process of phasing out animal testing in the development of monoclonal antibody therapies and other drugs to reduce research and development costs and, by extension, drug prices This policy brief describes how the new regulations relate to current and pending legislation, the alternative sources data can be derived from, and how this new regime could lead to cost savings in drug development.

Zenodo (CERN European Organization for Nuclear Research)
McGill University (CA)
Partnerships for the goals
Openalex Percentile: Top 39%
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.